



Faslodex[®] (fulvestrant) – First-time generic

- On May 31, 2019, [Sandoz launched](#) an [AO-rated](#) generic version of AstraZeneca's [Faslodex \(fulvestrant\)](#) injection.
 - Amneal received [FDA approval](#) of an [AO-rated](#) generic version of Faslodex on March 4, 2019. Launch plans for this generic are pending.
- Faslodex is approved as monotherapy for the treatment of:
 - Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or
 - HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.
- Faslodex is approved as combination therapy for the treatment of:
 - HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with [Kisqali[®] \(ribociclib\)](#) as initial endocrine based therapy or following disease progression on endocrine therapy
 - HR-positive, HER2-negative advanced or metastatic breast cancer in combination with [Ibrance[®] \(palbociclib\)](#) or [Verzenio[®] \(abemaciclib\)](#) in women with disease progression after endocrine therapy.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.